Satsuma Pharmaceuticals is a clinical-stage biopharmaceutical company engaged in developing a novel therapeutic product for the treatment of migraine. Its product candidate, STS101, is a drug-device combination of a dry-powder formulation of dihydroergotamine mesylate, or DHE, which can be self-administered with a pre-filled, single-use, nasaldelivery device.

Biotechnology

Health Care

Pharmaceutical

Therapeutics

Satsuma Pharmaceuticals, Inc.

Satsuma Pharmaceuticals, Inc.'s headquarters in South San Francisco, CA, United States

Rob Schultz

Diana Sayre

Alexander Majeska, PMP

Dave Prichard

Mic Iwashima

Roshni Flynn

Cindy Zhong, PMP

Description

People

Jobs